Released · Last reviewed
Jonathan Snipes, MD
Medical Reviewer
Jonathan Snipes, MD is the physician medical reviewer for GLP-1 Price Index. He reviews clinical guides, safety content and any page making medication-specific claims, checking mechanism, indication, contraindication and risk language against FDA labeling and primary clinical literature. His NPI record (1821250077) is listed in the CMS National Plan and Provider Enumeration System registry.
Credentials & verification
- Role
- Medical Reviewer
- NPI
- 1821250077 — verified in the CMS National Plan & Provider Enumeration System registry
- Review scope
- Physician-level medical review: medication guides, safety pages, dosing context, regulatory status.
- Verification
- NPI record checked against the CMS NPPES registry.
Conflict disclosure
Jonathan Snipes, MD is not compensated based on any reviewed provider's sales. Where a page involves NexLife, our ownership relationship is disclosed on that page, and the NexLife score is signed off by an unaffiliated reviewer. See our conflicts-of-interest policy.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
Role and scope
Dr. Jonathan Snipes, MD — Medical Reviewer. NPI 1821250077, verified against the CMS National Plan and Provider Enumeration System.
Dr. Snipes reviews medical claims for accuracy, and specifically for the boundary between what a trial demonstrated and what it did not — the distinction between an FDA-approved subcutaneous injection and a compounded preparation, between a randomised trial and an observational study, and between a trial mean and an individual promise.
What we publish, and what we deliberately do not
This profile contains only information that has been confirmed to us. We publish the name, the credential, the editorial role, the scope of review, and — where it exists — an NPI that we have checked against the CMS registry.
We do not publish specialty, board certification, state licence, hospital affiliation, university affiliation, awards, professional memberships, or biography unless each has been separately verified. Padding a reviewer profile with unverified professional detail is one of the commonest ways a health site manufactures authority, and we would rather this page look thin than look impressive on facts we cannot stand behind.
Conflict disclosure
Relationships the publisher has confirmed to date are named on the ownership disclosure. Where a provider is not named there, that is because the publisher has not confirmed a relationship — it is not a statement that we have verified its absence. We would rather show you that gap than imply an independence we have not checked.
Compensation does not increase the price you pay, and does not permit any provider to purchase a verification status, alter a documented fact, remove a material limitation, change a ranking, or bypass our published editorial and medical-review standards.
No reviewer on this site is compensated based on any provider’s sales, and no employee, executive or medical director of any reviewed provider writes, reviews, scores or approves that provider’s page. NexLife’s medical director, Dr. Adam Kennah, has no role in our editorial process. We name him on the NexLife review because he is a fact about NexLife — not because he has anything to do with our independence.
The numbers behind this page
How this page is kept current
Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
The molecule is chemically identical across every programme in the range. The $230 a month between the lowest and highest all-in semaglutide prices we read on October 15, 2026 ($49 and $279) is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.